title: Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids.
abstract: GLP-1 and exendin-4, which are used as insulin sensitizers or weight reducing drugs, were shown to improve glucose uptake in the heart. However, the direct effects of GLP-1 or exendin-4 on normal hearts in the presence of fatty acids, the main cardiac substrates, have never been investigated. We therefore assessed the effects of GLP-1 or exendin-4 on myocardial glucose uptake (GU), glucose oxidation (GO) and cardiac performance (CP) under conditions of fatty acid utilization.
  
  
  RESULTS
  Rat hearts were perfused with only glucose (5 mM) or glucose (5 mM) plus oleate (0.4 mM) as substrates for 60 min. After 30 min, GLP-1 or exendin-4 (0.5 nM or 5 nM) was added. In the absence of oleate, GLP-1 increased both GU and GO. Exendin-4 increased GO but showed no effect on GU. Neither GLP-1 nor exendin-4 affected CP. However, when oleate was present, GLP-1 failed to stimulate glucose utilization and exendin-4 even decreased GU. Furthermore, now GLP-1 reduced CP. In contrast to prior reports, this negative inotropic effect could not be blocked by the protein kinase A inhibitor H-89. We then measured myocardial GO and CP in rats receiving a 4-week GLP-1 infusion. Interestingly, this chronic treatment resulted in a significant reduction in both GO and CP.
  
  
  CONCLUSIONS
  Under the influence of oleate, GLP-1 reduces contractile function and fails to stimulate glucose utilization in normal hearts. Exendin-4 may acutely reduce cardiac glucose uptake but not contractility. We suggest advanced investigation of heart function and metabolism in patients treating with these peptides.
authors.affiliation: Department of Cardiothoracic Surgery, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.
authors.forename: T Dung
authors.initials: TD
authors.lastname: Nguyen
authors.forename: Yasushige
authors.initials: Y
authors.lastname: Shingu
authors.forename: Paulo A
authors.initials: PA
authors.lastname: Amorim
authors.forename: Michael
authors.initials: M
authors.lastname: Schwarzer
authors.forename: Torsten
authors.initials: T
authors.lastname: Doenst
mesh_terms: D000818:Animals; D005227:Fatty Acids / Q000378:metabolism* / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism* / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism*; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology*; D009924:Organ Culture Techniques; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D005227:Fatty Acids; D052216:Glucagon-Like Peptide 1; D005947:Glucose
keywords: Cardiac function; Cardiac glucose metabolism; Exendin-4; Glucagon-like peptide-1